

RHEUMATOLOGY REFERRAL FORM A-G

877.RxHyVee (877.794.9833) 10004 S. 152nd Street, Suite C Omaha, NE 68138

| Patient Information PLEASE FAX INSURANCE CARD (FRONT AND BACK) | | | | | Prescriber Information | | | | |
|--|---|----------------|------------------|---|---|-----------------------|----------------|------------------|-------------|
| Last Name | First Name | | DOB | | Practice/Facility Name | | | | |
| Address | | | | | Address | ess | | | |
| City State | | | ZIP | | City | State | ZIP | | |
| SSN | | | | | Prescriber Name | | | | |
| Sex ☐ Male ☐ Female Weight (kg) | | Height (ft,in) | | | Prescriber NPI | | | | |
| Emergency Contact | | Phone | | | Nurse/Key Contact Phone/Pag | | Phone/Page | ger | |
| Insurance Plan | | Plan ID # | | | Fax | | | | |
| Diagnosis/Clinical Information PLEASE FAX CLINICAL AND LAB INFORMATION | | | | | | | | | |
| Primary Diagnosis: M06.9 Rheumatoid Arthritis M08.00 Juvenile Rheumatoid Arthritis L40.59 Psoriatic Arthritis L40.54 Psoriatic Juvenile Arthritis M45.9 Ankylosing Spondylitis Other: Date of diagnosis/years with the disease: Prior Therapy: No Yes (provide details): Concurrent Therapy: No Yes (provide details): TB Test: No Yes (date): Results: | | | | | | | | | |
| Prescription Inform | ation | | | | | | | | |
| MEDICATION DOSE/STRENGTH | | | | DIRECTIONS I | DIRECTIONS FOR USE | | | | REFILLS |
| Actemra® IV Administration Current Weight: kg | 80 mg Vial 200 mg Vial 400 mg Vial | | | | 4 mg/kg IV once every 4 weeks Other: | | | | |
| Actemra® SC Administration Current Weight: kg | 162 mg (0.9 ml) PFS | | | | 162 mg SC every other week (<100 kg) 162 mg SC once a week (>/=100 kg) | | | | |
| Cimzia® Starter Dose: 200 mg/ml PFS 200 mg Lyophilized po | | | oowder vial | | Initial dose of 400 mg SC at weeks 0, 2, and 4 | | | 6 | 0 |
| | Maintenance Dose: 200 mg/ml PFS 200 mg Lyophilized powder vial | | | | 400 mg SC every 4 weeks 200 mg SC every 2 weeks | | | | |
| Cosentyx® | 150 mg/ml PFS 150 mg/ml Sensoready Pen | | | 150 mg SC 6 | No Loading Dose: 150 mg SC every 4 weeks 300 mg SC every 4 weeks | | | | |
| | | | | Loading Dose: 150 mg SC at weeks 0, 1, 2, and 3 300 mg SC at weeks 0, 1, 2, and 3 | | | | 4 8 | 0 |
| | | | | 150 mg SC a | Maintenance Dose: 150 mg SC at week 4, then 150 mg SC every 4 weeks thereafter 300 mg SC at week 4, then 300 mg SC every 4 weeks thereafter | | | | |
| Enbrel® Adult Dosing | 50 mg/ml Sureclick™ Autoinjector 50 mg/ml PFS Enbrel® Mini 50 mg/ml 25 mg Vial (inj supplies included) 25 mg /0.5 ml PFS | | | | Inject 50 mg SC once a week Other: | | | 4-week supply | |
| Enbrel® Pediatric Dosing Children ≥ 2 years old and adolescents Current weight:kg | 25 mg/0.5 ml PFS 25 mg Vial (inj supplies included) 50 mg/ml PFS Enbrel® Mini 50 mg /ml Sureclick™ Autoinjector | | | SC once wee | 63 kg: Inject 0.8 mg/kg (mg) C once weekly <i>(max 50 mg per dose)</i> 63 kg: Inject 50 mg SC once weekly (Children must weigh at east 138 pounds) | | | 4-week supply | |
| In order for a brand name produc substitution: | t to be dispensed, the pr | escriber must | t handwrite "Bra | and Necessary" or "Br | and Medically Necessary | ," or your state-spec | cific required | d language | to prohibit |

 $PRODUCT\,SUBSTITUTION\,PERMITTED/Brand\,exchange\,permitted\quad (date)$

DISPENSE AS WRITTEN/Do Not Substitute